FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
← catalyst calendarSponsored by Foghorn Therapeutics Inc. (industry) · FHTX — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
144estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-14 | actual | When the study began enrolling |
| Primary completion | Sep 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Hematologic Malignancy
- Relapsed Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Relapsed Myelodysplastic Syndromes
- Refractory Myelodysplastic Syndromes
- Relapsed Chronic Myelomonocytic Leukemia
- Refractory Chronic Myelomonocytic Leukemia
Interventions
- Drug: FHD-286
- Drug: Low Dose Cytarabine — also filed as LDAC
- Drug: Decitabine
Primary outcome
what the primary-completion date above is the date OFIncidence of AEs, dose-limiting toxicities (DLTs), serious AEs (SAEs), AEs leading to discontinuation, and adverse events of special interest (AESIs); safety laboratory assessments
measured Up to 18 months
Publications
- PMID 40238563 — reports results
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · FHTX's whole pipeline · Catalyst calendar · Every registered study · What changed